{"entity":{"id":"loi-sherene","kind":"person","name":"Sherene Loi","aka":[],"tldr":"Showed that immune cells inside breast tumours predict outcome, the basis for de-escalating chemotherapy in TNBC.","summary":"Sherene Loi is Professor and Head of the Translational Breast Cancer Genomics and Therapeutics Laboratory at the Peter MacCallum Cancer Centre in Melbourne, where she is also a medical oncologist. Her work on tumour-infiltrating lymphocytes established them as a prognostic and predictive biomarker in breast cancer, showing that immune cells inside tumours predict outcome and underpinning current efforts to spare patients with stage I triple-negative breast cancer from chemotherapy. Her publications include a pooled individual patient analysis of tumour-infiltrating lymphocytes and prognosis in early-stage triple-negative breast cancer. She leads immunotherapy trials, including work connected to KEYNOTE-522, and chairs the International Immuno-Oncology Biomarker Working Group.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Sherene_Loi","links":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Loi%20S%5BAuthor%5D%20tumor%20infiltrating%20lymphocytes%20breast"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["peter-mac"],"pathways":[],"terms":["tils"],"trials":["keynote-522"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Head, Translational Breast Cancer Genomics and Therapeutics Laboratory; medical oncologist, Peter Mac","institutionId":"peter-mac","specialisms":["Breast cancer","Tumour-infiltrating lymphocytes","Immunotherapy","Triple-negative breast cancer"],"profiles":[{"label":"Peter MacCallum Cancer Centre","url":"https://www.petermac.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Loi%20S%5BAuthor%5D%20tumor%20infiltrating%20lymphocytes%20breast"}],"papers":[{"title":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","journal":"Journal of Clinical Oncology","year":2019,"doi":"10.1200/JCO.18.01010"},{"title":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2305488","doi":"10.1056/NEJMoa2305488"}]},"route":"/people/loi-sherene/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"institution":[{"id":"bcrf","kind":"institution","name":"Breast Cancer Research Foundation","route":"/institutions/bcrf/"},{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/"}],"term":[{"id":"tils","kind":"term","name":"Tumour-infiltrating lymphocytes (TILs)","route":"/terms/tils/"}],"trial":[{"id":"keynote-522","kind":"trial","name":"KEYNOTE-522","route":"/trials/keynote-522/"}],"paper":[{"id":"paper-natalee-nejm-2024","kind":"paper","name":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","route":"/key-papers/paper-natalee-nejm-2024/"},{"id":"paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021","kind":"paper","name":"PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer","route":"/key-papers/paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021/"},{"id":"paper-park-tils-untreated-early-tnbc-ann-oncol-2019","kind":"paper","name":"Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy","route":"/key-papers/paper-park-tils-untreated-early-tnbc-ann-oncol-2019/"},{"id":"paper-loi-tils-pooled-early-tnbc-jco-2019","kind":"paper","name":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","route":"/key-papers/paper-loi-tils-pooled-early-tnbc-jco-2019/"},{"id":"paper-leon-ferre-tils-tnbc-no-chemotherapy-jama-2024","kind":"paper","name":"Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer","route":"/key-papers/paper-leon-ferre-tils-tnbc-no-chemotherapy-jama-2024/"}],"company":[{"id":"breast-cancer-trials","kind":"company","name":"Breast Cancer Trials","route":"/companies/breast-cancer-trials/"}]}}